Front-line Indian firms have thrown down the gauntlet to Boehringer Ingelheim GmbH with the launch on the domestic market of their cut-price versions of nintedanib for idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterized by a decline in lung function.
First off the block appears to have been Sun Pharmaceutical Industries Ltd., the country’s top-ranked drug firm, which signaled...







